In our study, we established PSMD1 as a negative prognostic factor in oropharyngeal squamous cell carcinoma, indicating its potential as a target for targeted therapy and paving the way for future in vitro studies on drug repositioning. This evidence concerns the gene PSMD1 and oropharynx squamous cell carcinoma.